Aclaris Therapeutics Announces Pricing of $50.0 Million Offering of Common Stock and Pre-Funded Warrants
Key Highlights
- ➤Aclaris (ACRS) priced a $50.0 million underwritten stock and pre-funded warrant offering
- ➤Investors will buy 7,785,714 shares at $3.50 per share
- ➤Pre-funded warrants cover 6,500,000 shares at $3.49999 purchase price
- ➤Offering expected to close October 28, 2026, pending customary conditions
Expert Statements
Will Roberts, Senior Vice President, Corporate Communications and Investor Relations at Aclaris Therapeutics
“Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995.”
WAYNE, Pa., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced the pricing of an underwritten offering of 7,785,714 shares of its common stock at a price of $3.50 per share and, in lieu of shares of common stock to certain investors, pre-funded warrants to purchase 6,500,000 shares of common stock at a purchase price of $3.49999 per share, which equals the offering price per share of the common stock less the $0.00001 exercise price per share of each pre-funded warrant. All of the shares of common stock and the pre-funded warrants are to be sold by Aclaris.
The offering includes participation from TCGX, RA Capital Management, Invus and a large mutual fund.
Get started
Create a free account to read the full story.